facebook twitter youtube

News archive

Recent news


As part of Myeloma Patients Europe’s (MPE) ongoing work to ensure that the patient voice is fully represented, and to strengthen organizations’ and individuals’ ability to advocate effectively, in 2017 MPE created the Advocate Development Program (ADP). The ADP is a 12-month training programme designed to develop participants’ advocacy knowledge and skills to better serve patients locally, nationally, and across Europe. Through the course, participants improve their understanding of clinical research and development, mechanisms of accessing diagnostics and drugs, interaction with stakeholders including clinicians and industry, and the basics of evidence-based advocacy. Continue reading


The pharmaceutical company Oncopeptides has announced that the first patient has been enrolled in the OP-201 study. This is an open-label, phase 1/2 study to evaluate melflufen and dexamethasone in AL amyloidosis patients, following at least one prior line of therapy. This is the first study to explore the effect of melflufen outside of myeloma. Continue reading


The US Food and Drug Administration (FDA) has approved belantamab mafodotin (BLENREP) as a monotherapy treatment for adult patients with relapsed or refractory myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This drug is the first anti-BCMA (B-cell maturation antigen) therapy approved anywhere in the world. Continue reading

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of belantamab mafodotin as monotherapy for the treatment of myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Continue reading


The Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Haematology (HARMONY) is working to define a set of treatment outcomes (COS) by using a multi-round survey (known as a Delphi survey) to reach consensus amongst patients and other stakeholder groups. Continue reading

1 2 3 22